RPL34P23

Across TCGA pan-cancer cohorts, RPL34P23 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL34P23’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where RPL34P23 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL34P23 is over-expressed in tumor.

PRAD, LIHC, and COAD are the cancer types where RPL34P23 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL34P23 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.034	.044	2	view →
LIHC	All	All	+0.018	.023	2	view →
COAD	All	All	+0.065	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RPL34P23–PRAD

Open the PRAD breakdown →